Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Novel drug puts cancer cells under extreme metabolic stress

Cancer cells have a voracious appetite for sugar-using it to fuel their rapid growth. This is why many scientists have tried to develop drugs that block cancer cells' metabolism by cutting off their sugar supply. Now a team led by researchers at The University

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Cancer cells have a voracious appetite for sugar-using it to fuel their rapid growth. This is why many scientists have tried to develop drugs that block cancer cells' metabolism by cutting off their sugar supply.

Now a team led by researchers at The University of Texas at Austin report in the journal Nature Chemical Biology that they have found a completely different approach. Instead of starving cancer cells, they trick them into consuming even more sugar than usual. Then, at the same time, the drug blocks their backup fuel source-fat.

By attacking both fuel sources at once, the experimental drug puts cancer cells under so much stress that many of them die. They demonstrated the drug's effectiveness at treating an aggressive form of melanoma in mice.

I like to think of this technology like a two-headed dragon. We are putting one part of the cell into overdrive while simultaneously weakening another part. It appears to be extremely potent." Xiaolu (Lulu) Lim Ang Cambronne, associate professor of molecular biosciences at UT and co-corresponding author

In lab experiments, the drug was effective against several types of human cancer cells, including melanoma, leukemia, breast cancer, lung cancer, liver cancer and neuroblastoma. In the mice with melanoma, most cancer cells died, while non-cancerous cells were much less affected.

Drugs that attack cancer with this kind of one-two punch are not totally new. A growing class of compounds called antibody-drug conjugates (ADCs) use an antibody to target cancer cells, then deliver a payload of chemotherapy right to the tumor. But ADCs have many limitations.

"Antibodies are difficult to make, and because they're so large they're only able to target proteins in the surface of cancer cells," said Ken Hsu, an associate professor of chemistry at UT and co-corresponding author. "We think of this new compound as a fully chemical counterpart to ADCs. They are much easier to manufacture. And because they are smaller, they are able to target even proteins that are inside cells."

This work was supported by the National Institutes of Health, the National Institute of General Medical Sciences, the Cancer Prevention and Research Institute of Texas (CPRIT), the University of Washington Beckman Cryo-EM Center, West Virginia University's Visual Sciences CoBRE program, the Melanoma Research Alliance, the Mark Foundation for Cancer Research, The Welch Foundation and Tito's Handmade Vodka.

The drug has two parts. The targeting agent, a molecule called XJ-4-85, acts on an enzyme called PFKL, speeding up glycolysis (the breakdown of sugar) inside cancer cells. After the XJ-4-85 binds, it releases its payload, a compound that acts on another enzyme called CPT2. CPT2 normally helps cells break down fatty acids for energy. By disrupting both of the cells' major energy sources at the same time, it shuts down cancer growth.

"The way this drug works was totally unexpected," said Xiaoding Jiang, a postdoctoral fellow in the Hsu Lab, who designed the molecule. "A lot of research was required to figure out what it was doing on the molecular level. We were also surprised to see how selectively it binds to cancer cells."

The research is still in its early stages. Although the results are promising, much more laboratory testing is needed before the drug can be studied in people.

Beyond this particular drug, the researchers say this research also illustrates a new broader approach for designing these two-part medicines, which they call "electrophile-drug conjugates" or EDCs. "They have the potential to be useful beyond cancer, for other kinds of diseases as well," Cambronne said.

The team members emphasize the importance of collaboration in making this discovery possible, bringing together experts from across UT-and beyond. "This project took a village," said Hsu, a CPRIT Scholar.

The study's other UT authors are Congcong Lyu, Crystal Wilson, Scott Lyons, Mu-Jie Lu, Shuangyu Luo, Gibae Kim, Hsin-Ru Chan, Wesley Wolfe and Yi-Chih Lin. Authors also include Eric Lynch, Lauren Salay and Justin M. Kollman from the University of Washington in Seattle; Hayden Hess and Bradley Webb from West Virginia University; and Lauren Zacharias and Thomas Mathews from Children's Medical Center Research Institute at The University of Texas Southwestern Medical Center.

Jiang, X., et al. (2026). A covalent PFKL activator suppresses tumor growth. Nature Chemical Biology. DOI: 10.1038/s41589-026-02289-9. https://www.nature.com/articles/s41589-026-02289-9

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Your early research focused on predicting molecular properties such as solubility using machine learning. What did that teach you about data-driven property prediction?

Data-driven models, such as Quantitative Structure Activity Relationships (QSAR), are incredibly attractive because they offer rapid methods for predicting molecular properties, including those that are difficult to access through fundamental chemical and physical theory. For new molecules, in related regions of chemical space to the training data, they can often be very accurate. The challenge is that they typically do not generalize across large diverse chemical and biological spaces. Therefore real care is needed when applying them to novel chemistry or biology. Some attempts to build more widely applicable QSAR models have been made in recent years, but most models in use today are still built for specific chemistries and properties owing to the scale and complexity of chemical space. When I started this work, especially for solubility predictions, the datasets were modest by today’s standards, often hundreds to a few thousand molecules. One of the first things that teaches you is to explore the data carefully, assess its quality and quantity, and only then move forward with modeling. The aim is to capture genuine relationships between numerical molecular descriptions and important target endpoints, but those relationships may be only locally generalizable. I also think the phrase “simple descriptors” is interesting. Some are simple, such as atom counts or bond counts, but others rely on detailed parameterization, group contributions, and graph-theoretical techniques. We still see these descriptors used today, sometimes alongside embeddings from graph neural networks or language models. The main lesson for me is that there is no single workflow. Each dataset, model, and end-use case needs careful thought.

Source: www.news-medical.net ↗
02What supplements really work?

The bulk of vitamins and supplements containing fish oil, biotin, and vitamins A, C, and E can potentially promote nail and hair growth. You can find dietary supplements with higher concentrations of vitamins and minerals that aid skin, hair, and nail health. Fish oil supplements make nails and hair shiny. Fish oil also serves as an agent that can decrease signs of aging. If sun exposure damages the skin, the omega-3 fatty acids in fish oil can help. Biotin, also known as B7, increases hair density and strengthens it. It is found naturally in bananas, eggs, and milk. Vitamins are vital for skin health as well. Vitamin A reduces acne flairs and helps with changes due to aging like wrinkling. A vitamin A deficiency may increase the risk of acne because it becomes difficult for dead skin to slough off hair follicles, blocking pores. Vitamin B lowers the risk of precancerous growths and nonmelanoma skin cancer. Vitamin C is an antioxidant. It leads the fight against free radicals to help stimulate collagen and brighten skin. It also helps to prevent the formation of unneeded melanin that causes uneven skin pigmentation.

Source: www.medicinenet.com ↗
03What do you think the future holds for deep learning with regards to drug discovery?

I think we're only just scratching the surface at the moment. I think over the next couple of years, we'll start to see some major strides. Obviously, showing the effects on target identification takes some time with new molecules but, certainly, the repositioning effects should be seen in a few years. I think there is great promise in terms of being able to really tap into a much broader chemical space, so we can have a much wider and more varied chemical palette to be able to pick the best molecules for drug discovery from. Also, accelerating the ways in which we can look at the data and glean much more information from it can help us both in terms of patient selection for clinical trials and in terms of being able to pick up signals of efficacy and safety much earlier.

Source: www.news-medical.net ↗
04What is carb cycling?

Carb cycling is an attempt to fine-tune your carbohydrate consumption to alter many aspects of your metabolism. Your plan will include the same protein intake each day but vary carbohydrates according to your activity. Your carb cycling plan may have three low or zero carb days, two moderate carb days, and two high carb days. Meeting your calorie requirements will require including more fats on low-carb days. Carb cycling needs much more planning than a usual calorie-controlled diet. One way is to match your carb cycling to your physical activity. If you go to the gym thrice a week, you could have carbs on those days. The carbs provide energy for your workout, prevent fatigue, and avoid the muscle loss sometimes seen with dieting. The days when you eat little to no carbs force your body to generate energy from other sources, like proteins and fats. But the days when you eat more carbohydrates might reverse this change. You must only eat a high-carb diet on the days you have a heavy workout, which uses up the calories.

Source: www.medicinenet.com ↗
05What comes next?

We are now testing the drug in patients with earlier-stage pancreatic cancer, prescribing it while their tumors are still operable and before their cancer spreads.

Source: www.news-medical.net ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →